NASDAQ:ADMA ADMA Biologics (ADMA) Stock Price, News & Analysis → The world’s greatest investment (From Porter & Company) (Ad) Free ADMA Stock Alerts $5.94 -0.05 (-0.83%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$5.93▼$6.0550-Day Range$4.93▼$6.3452-Week Range$2.94▼$6.41Volume2.88 million shsAverage Volume2.78 million shsMarket Capitalization$1.36 billionP/E RatioN/ADividend YieldN/APrice Target$7.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get ADMA Biologics alerts: Email Address ADMA Biologics MarketRank™ Stock AnalysisAnalyst RatingBuy3.25 Rating ScoreUpside/Downside26.3% Upside$7.50 Price TargetShort InterestHealthy2.94% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.31Based on 12 Articles This WeekInsider TradingSelling Shares$3.63 M Sold Last QuarterProj. Earnings Growth66.67%From $0.30 to $0.50 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.64 out of 5 starsMedical Sector282nd out of 947 stocksBiological Products, Except Diagnostic Industry36th out of 159 stocks 3.6 Analyst's Opinion Consensus RatingADMA Biologics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.50, ADMA Biologics has a forecasted upside of 26.3% from its current price of $5.94.Amount of Analyst CoverageADMA Biologics has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.94% of the outstanding shares of ADMA Biologics have been sold short.Short Interest Ratio / Days to CoverADMA Biologics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ADMA Biologics has recently increased by 9.27%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldADMA Biologics does not currently pay a dividend.Dividend GrowthADMA Biologics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADMA. Previous Next 3.0 News and Social Media Coverage News SentimentADMA Biologics has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for ADMA Biologics this week, compared to 4 articles on an average week.Search Interest43 people have searched for ADMA on MarketBeat in the last 30 days. This is an increase of 231% compared to the previous 30 days.MarketBeat Follows32 people have added ADMA Biologics to their MarketBeat watchlist in the last 30 days. This is an increase of 220% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ADMA Biologics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,627,348.00 in company stock.Percentage Held by InsidersOnly 6.00% of the stock of ADMA Biologics is held by insiders.Percentage Held by Institutions73.58% of the stock of ADMA Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for ADMA Biologics are expected to grow by 66.67% in the coming year, from $0.30 to $0.50 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ADMA Biologics is -45.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ADMA Biologics is -45.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioADMA Biologics has a P/B Ratio of 9.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About ADMA Biologics Stock (NASDAQ:ADMA)ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Read More ADMA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADMA Stock News HeadlinesMarch 17, 2024 | insidertrades.comSteve Elms Sells 183,008 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) StockMarch 16, 2024 | insidertrades.comSteve Elms Sells 407,000 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) StockMarch 19, 2024 | The Bull Report (Ad)The AI Bottleneck No One is Talking AboutRenewable energy is growing at an impressive speed - but not fast enough. This could be one of the greatest periods for the nuclear industry ever.March 18, 2024 | americanbankingnews.comADMA Biologics, Inc. (NASDAQ:ADMA) Director Sells $2,527,470.00 in StockMarch 17, 2024 | investing.comAdma Biologics director Steve Elms sells over $6.3 million in company stockMarch 17, 2024 | americanbankingnews.comShort Interest in ADMA Biologics, Inc. (NASDAQ:ADMA) Increases By 9.3%March 16, 2024 | finance.yahoo.comADMA Apr 2024 5.000 putMarch 15, 2024 | finance.yahoo.comAdma Biologics (ADMA) Stock Moves -0.5%: What You Should KnowMarch 19, 2024 | Colonial Metals (Ad)Central Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.March 13, 2024 | americanbankingnews.comADMA Biologics (NASDAQ:ADMA) Hits New 52-Week High at $6.44March 12, 2024 | americanbankingnews.comADMA Biologics, Inc. (NASDAQ:ADMA) Receives Average Rating of "Buy" from AnalystsMarch 11, 2024 | finanznachrichten.deADMA Biologics, Inc.: ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV & BIVIGAMMarch 11, 2024 | globenewswire.comADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®March 5, 2024 | globenewswire.comADMA Biologics to Participate in the Raymond James Institutional Investor ConferenceMarch 1, 2024 | seekingalpha.comADMA Biologics, Inc. (ADMA) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | finance.yahoo.comADMA Biologics Full Year 2023 Earnings: EPS Misses ExpectationsFebruary 29, 2024 | uk.finance.yahoo.comQ4 2023 ADMA Biologics Inc Earnings CallFebruary 29, 2024 | finanznachrichten.deADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 29, 2024 | finanznachrichten.deADMA Biologics, Inc.: ADMA Biologics Announces CFO TransitionFebruary 29, 2024 | finance.yahoo.comADMA Biologics, Inc. (NASDAQ:ADMA) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | markets.businessinsider.comForecasting The Future: 4 Analyst Projections For ADMA BiologicsFebruary 28, 2024 | msn.comADMA Biologics GAAP EPS of -$0.08 misses by $0.11, revenue of $73.9M beats by $0.93MFebruary 28, 2024 | msn.comADMA Biologics' CFO to step downFebruary 28, 2024 | marketwatch.comADMA Biologics Says CFO Brian Lenz Moving to Consulting RoleFebruary 28, 2024 | finance.yahoo.comADMA Biologics Inc Reports Robust Revenue Growth and Positive Adjusted Net Income for FY 2023February 28, 2024 | globenewswire.comADMA Biologics Announces CFO TransitionFebruary 28, 2024 | globenewswire.comADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateSee More Headlines Receive ADMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2023Today3/19/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ADMA CUSIPN/A CIK1368514 Webwww.admabiologics.com Phone(201) 478-5552Fax201-478-5553Employees617Year FoundedN/APrice Target and Rating Average Stock Price Target$7.50 High Stock Price Target$10.00 Low Stock Price Target$6.00 Potential Upside/Downside+26.3%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.13) Trailing P/E RatioN/A Forward P/E Ratio19.80 P/E GrowthN/ANet Income$-28,240,000.00 Net Margins-10.94% Pretax Margin-10.94% Return on Equity0.49% Return on Assets0.21% Debt Debt-to-Equity Ratio1.04 Current Ratio5.16 Quick Ratio1.69 Sales & Book Value Annual Sales$258.21 million Price / Sales5.25 Cash Flow$0.05 per share Price / Cash Flow118.46 Book Value$0.60 per share Price / Book9.90Miscellaneous Outstanding Shares228,220,000Free Float214,527,000Market Cap$1.36 billion OptionableOptionable Beta0.43 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Adam S. Grossman (Age 47)Co-Founder, President, CEO & Director Comp: $1.52MDr. Jerrold B. Grossman D.P.S. (Age 76)Ph.D., Co-Founder & Vice Chairman of the Board Comp: $80kMr. Brian Lenz CPA (Age 52)Executive VP, CFO & GM of ADMA BioCenters Comp: $1.08MMs. Kaitlin KestenbergSenior Vice President of Compliance & Project OperationsMr. Drew PantelloVice President of Marketing & Corporate DevelopmentMr. Neal C. FitzpatrickVice President of SalesMs. Cindy PetersenExecutive Director of Human ResourcesMr. Skyler BloomSenior Director of Business Development & Corporate StrategyMore ExecutivesKey Competitors4D Molecular TherapeuticsNASDAQ:FDMTAdaptimmune TherapeuticsNASDAQ:ADAPAutolus TherapeuticsNASDAQ:AUTLRelay TherapeuticsNASDAQ:RLAYCARGO TherapeuticsNASDAQ:CRGXView All CompetitorsInsiders & InstitutionsSteve ElmsSold 183,008 sharesTotal: $1.10 M ($6.01/share)Steve ElmsSold 407,000 sharesTotal: $2.53 M ($6.21/share)Vanguard Group Inc.Bought 110,180 shares on 3/11/2024Ownership: 5.649%Wellington Management Group LLPBought 213,985 shares on 3/5/2024Ownership: 0.095%Goldman Sachs Group Inc.Sold 515,229 shares on 3/1/2024Ownership: 0.767%View All Insider TransactionsView All Institutional Transactions ADMA Stock Analysis - Frequently Asked Questions Should I buy or sell ADMA Biologics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADMA shares. View ADMA analyst ratings or view top-rated stocks. What is ADMA Biologics' stock price target for 2024? 4 brokers have issued 12 month target prices for ADMA Biologics' stock. Their ADMA share price targets range from $6.00 to $10.00. On average, they predict the company's share price to reach $7.50 in the next year. This suggests a possible upside of 26.3% from the stock's current price. View analysts price targets for ADMA or view top-rated stocks among Wall Street analysts. How have ADMA shares performed in 2024? ADMA Biologics' stock was trading at $4.52 at the start of the year. Since then, ADMA shares have increased by 31.4% and is now trading at $5.94. View the best growth stocks for 2024 here. Are investors shorting ADMA Biologics? ADMA Biologics saw a increase in short interest during the month of February. As of February 29th, there was short interest totaling 6,720,000 shares, an increase of 9.3% from the February 14th total of 6,150,000 shares. Based on an average daily volume of 2,540,000 shares, the short-interest ratio is presently 2.6 days. View ADMA Biologics' Short Interest. When is ADMA Biologics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our ADMA earnings forecast. How were ADMA Biologics' earnings last quarter? ADMA Biologics, Inc. (NASDAQ:ADMA) issued its quarterly earnings results on Wednesday, November, 8th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.01). The biotechnology company earned $67.30 million during the quarter, compared to analysts' expectations of $62.13 million. ADMA Biologics had a negative net margin of 10.94% and a positive trailing twelve-month return on equity of 0.49%. The firm's revenue was up 63.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.08) earnings per share. What ETF holds ADMA Biologics' stock? Virtus LifeSci Biotech Products ETF holds 88,335 shares of ADMA stock, representing 1.90% of its portfolio. What guidance has ADMA Biologics issued on next quarter's earnings? ADMA Biologics updated its FY 2025 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $380.0 million-. What is Adam S. Grossman's approval rating as ADMA Biologics' CEO? 9 employees have rated ADMA Biologics Chief Executive Officer Adam S. Grossman on Glassdoor.com. Adam S. Grossman has an approval rating of 29% among the company's employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of ADMA Biologics own? Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania Real Estate Investment Trust (PEI), Organigram (OGI), Gran Tierra Energy (GTE), Tilly's (TLYS), Bionano Genomics (BNGO), Novan (NOVN), CNBX Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT). Who are ADMA Biologics' major shareholders? ADMA Biologics' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.71%), Vanguard Group Inc. (5.65%), Nuveen Asset Management LLC (5.03%), Stonepine Capital Management LLC (4.08%), Perceptive Advisors LLC (2.85%) and Assenagon Asset Management S.A. (1.75%). Insiders that own company stock include Adam S Grossman, Brian Lenz, Bryant Fong, Jerrold B Grossman, Perceptive Advisors Llc, Steve Elms and Young Kwon. View institutional ownership trends. How do I buy shares of ADMA Biologics? Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ADMA) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportThe world’s greatest investmentPorter & CompanyMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADMA Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.